Emalex Biosciences, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
24
Active:5
Completed:13
Trial Phases
3 Phases
Phase 1:15
Phase 2:5
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (23 trials with phase data)• Click on a phase to view related trials
Phase 1
15 (65.2%)Phase 2
5 (21.7%)Phase 3
3 (13.0%)Expanded Access Program for Treatment With Ecopipam for Tourette's Disorder
- Conditions
- Tourettes Disorder
- First Posted Date
- 2025-07-30
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- Emalex Biosciences Inc.
- Registration Number
- NCT07093541
Food-effect Study of Ecopipam Pharmacokinetics
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Emalex Biosciences Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT06669091
- Locations
- 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States
Drug Interaction Study
Phase 1
Completed
- Conditions
- Drug Interaction
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Emalex Biosciences Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT06194864
- Locations
- 🇨🇦
Syneos Health Clinic Inc., Québec, Quebec, Canada
A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Emalex Biosciences Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06021522
- Locations
- 🇺🇸
Harmonex, Inc., Dothan, Alabama, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Advanced Research Center, Anaheim, California, United States
Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization
Phase 1
Completed
- Conditions
- QT/QTc
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Emalex Biosciences Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT05841160
- Locations
- 🇺🇸
PPD Austin Phase 1 Clinical Research Unit, Austin, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found